Vaxart
Stock Forecast, Prediction & Price Target
Vaxart Financial Estimates
Vaxart Revenue Estimates
Vaxart EBITDA Estimates
Vaxart Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $892K N/A | $107K -88.00% | $7.37M 6796.26% | Avg: $31.76M Low: $31.69M High: $31.84M avg. 330.50% | Avg: $43.2M Low: $43.09M High: $43.30M avg. 35.99% | ||
Net Income
% change YoY
| $-70.47M N/A | $-107.75M -52.91% | $-82.46M 23.47% | Avg: $-112.48M Low: $-88.34M High: $-56.47M avg. -36.40% | Avg: $-115.68M Low: $-85.44M High: $-59.37M avg. -2.84% | ||
EBITDA
% change YoY
| $-61.66M N/A | $-96.32M -56.19% | $-74.72M 22.42% | Avg: $-30.00M Low: $-30.07M High: $-29.93M avg. 59.85% | Avg: $-40.79M Low: $-40.89M High: $-40.70M avg. -35.99% | ||
EPS
% change YoY
| -$0.58 N/A | -$0.84 -44.82% | -$0.57 32.14% | Avg: -$0.5 Low: -$0.61 High: -$0.39 avg. 12.86% | Avg: -$0.49 Low: -$0.59 High: -$0.41 avg. 0.67% | ||
Operating Expenses
% change YoY
| $70.63M N/A | $110.44M 56.34% | $90.72M -17.85% | Avg: $1.94B Low: $1.93B High: $1.94B avg. 2042.92% | Avg: $2.64B Low: $2.63B High: $2.65B avg. 35.99% | ||
FAQ
What is Vaxart stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -19.62% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is -88.34M, average is -112.48M and high is -56.47M.
What is Vaxart stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 183.24% in 2025-2026.
We have gathered data from 2 analysts. Their low revenue estimate is $31.69M, average is $31.76M and high is $31.84M.
What is Vaxart stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 6.76% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.61, average is -$0.5 and high is $-0.39.
What is the best performing analyst?
In the last twelve months analysts have been covering Vaxart stock. The most successful analyst is Mayank Mamtani.